Clinical investigations of RPE65 gene augmentation therapy in LCA patients (Luxturna®) showed the safety of AAV-mediated gene delivery and improved functional vision in certain individuals (Bennett et al. 2016; Russell et al. 2017). The gene discussed is RPE65; the disease is Leber congenital amaurosis.